Interim Results
02 Janvier 2007 - 8:03AM
UK Regulatory
RNS Number:8189O
Cytomyx Holdings PLC
02 January 2007
Cytomyx Holdings Plc
Interim results for the six months ended 30 September 2006
CHAIRMAN'S STATEMENT
Cytomyx PLC is going through significant changes. In November, I was named by
the board to take charge of the company. Although this company had significant
financial difficulties, I believe there are interesting business opportunities
moving forward.
With the complete of human genome project, the field of individualised medicine
is increasing becoming a clinical reality. The centrepiece of individualised
medicine is the discovery and validation of clinically important biomarkers
which can improve significantly the diagnosis and treatment of various diseases.
Cytomyx LLC, the remaining core business unit of Cytomyx PLC, is uniquely
positioned as a potential leader in the field of biomarker discovery and
validation. The company has collected over 200,000 clinically important human
tissue samples over the years and has over 100 customers who rely on Cytomyx's
tissue repository and clinical data for biomarker discovery and validation.
We are planning to change our core business of a pure biorepository into a human
tissue based biomarker discovery and validation company. For this reason, we are
positioning the company as "Cytomyx-The Biomarker Company". This is a very
exciting and dynamic market. We believe that there will be significant value to
be created in this field.
Wei-Wu He, Ph.D.
Chairman and CEO
CONSOLIDATED PROFIT AND LOSS ACCOUNT
Six months ended 30 September 2006
2006 (unaudited)
#
Notes
TURNOVER
Existing operations 468,048
Turnover - continuing operations 468,048
Turnover 468,048
Cost of sales (1,242,325)
Gross profit (774,277)
Administrative expenses (1,411,965)
OPERATING LOSS
Existing operations (2,173,757)
Operating loss (2,173,757)
LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (2,173,757)
Tax on loss on ordinary activities 43,475
LOSS FOR THE FINANCIAL PERIOD (2,130,282)
Loss per ordinary share (pence) 2 (3.66)
Diluted loss per ordinary share (pence) 2 (3.66)
CONSOLIDATED STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
Six months ended 30 September 2006
2006 (unaudited)
#
Loss for the year (2,130,282)
Currency translation difference (20,249)
TOTAL GAINS AND LOSSES RECOGNISED IN THE YEAR (2,150,531)
CONSOLIDATED BALANCE SHEET
September 30, 2006
2006 (unaudited)
#
FIXED ASSETS
Intangible assets 847,686
Tangible assets 368,903
1,216,589
CURRENT ASSETS
Stocks 396,518
Debtors - Due with one year 126,379
Cash at bank and in hand 98,748
621,645
CREDITORS: amounts falling due
within one year (457,798)
NET CURRENT ASSETS 163,847
TOTAL ASSETS LESS CURRENT LIABILITIES 1,380,436
NET ASSETS 1,380,436
CAPITAL AND RESERVES
Called up share capital 1,546,456
Share premium account 9,072,552
Share capital to be issued 148,750
Merger reserve 945,000
Profit and loss account (10,332,322)
EQUITY SHAREHOLDERS' FUNDS 1,380,436
CONSOLIDATED CASH FLOW STATEMENT
Six months ended 30 September 2006
2006 (unaudited)
#
Net cash outflow from operating activities (1,817,261)
Returns on investments and servicing of finance (310,149)
Taxation 55,654
Capital expenditure and financial investment (112,982)
Net cash outflow before management of liquid resources (2,184,738)
and financing
Financing 875,474
Decrease in cash in the year (1,309,264)
RECONCILIATION OF OPERATING LOSS TO NET CASH OUTFLOW FROM OPERATING ACTIVITIES
2006 (unaudited)
#
Operating loss (2,130,282)
Depreciation charge 21,518
Amortisation of goodwill and intangibles 4,913
Decrease in debtors 1,068,244
Increase in creditors (781,654)
Net cash outflow from operating activities (1,817,261)
1. BASIS OF PREPARATION
These interim financial statements for the twelve months ended 30 September
2006 and 2005 are unaudited and do not constitute statutory financial statements
within the meaning of section 240 of the Companies Act 1985.
These interim financial statements comply with relevant accounting standards and
have been prepared on a consistent basis using accounting policies set out in
the 2005 Annual Report.
2. LOSS PER ORDINARY SHARE
The loss per share is based on the weighted average number of shares and is
presented as if the share consolidation had happened at the beginning of the
first period presented within these interim financial statements.
The calculations of basic and diluted loss per ordinary share are based on a
loss of #2,130,282 (30 September 2005 - #2,307,595) and on 58,125,182 (30
September 2004 - 47,974,948) ordinary shares being the weighted average number
of ordinary shares in issue during the period.
3. RELATED PARTY TRANSACTIONS
On 15 September 2005 the group sold 100% of its holding in Cambridge Bioscience
Limited to A Seeley (a former director) for the exchange of #164,034 of cash and
the cancellation of loans amounting to #727,975, which were payable to A Seeley.
The loss on disposal created by the sale of Cambridge Bioscience Limited
amounted to #769,521.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR OKDKDPBKDKDK
Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024